Blue Trust Inc. Has $482,000 Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Blue Trust Inc. raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 30.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 829 shares of the medical research company’s stock after purchasing an additional 193 shares during the period. Blue Trust Inc.’s holdings in Thermo Fisher Scientific were worth $482,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at $2,909,524,000. Capital World Investors raised its position in Thermo Fisher Scientific by 10.0% in the first quarter. Capital World Investors now owns 13,493,852 shares of the medical research company’s stock worth $7,842,762,000 after purchasing an additional 1,231,059 shares in the last quarter. Swedbank AB acquired a new stake in Thermo Fisher Scientific during the first quarter valued at approximately $705,636,000. Veritas Asset Management LLP raised its holdings in shares of Thermo Fisher Scientific by 70.1% in the 4th quarter. Veritas Asset Management LLP now owns 1,692,148 shares of the medical research company’s stock worth $898,175,000 after buying an additional 697,383 shares in the last quarter. Finally, Winslow Capital Management LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $333,786,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, VP Lisa P. Britt sold 3,624 shares of the business’s stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the sale, the vice president now directly owns 13,699 shares of the company’s stock, valued at $8,397,760.98. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, VP Lisa P. Britt sold 3,624 shares of the company’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $613.02, for a total transaction of $2,221,584.48. Following the completion of the sale, the vice president now owns 13,699 shares in the company, valued at $8,397,760.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph R. Holmes sold 860 shares of the firm’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $611.03, for a total value of $525,485.80. Following the transaction, the chief accounting officer now owns 1,814 shares in the company, valued at $1,108,408.42. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,084 shares of company stock worth $19,767,092. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.0 %

NYSE TMO traded up $0.29 on Friday, hitting $603.98. 1,076,197 shares of the company were exchanged, compared to its average volume of 1,714,754. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $622.30. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The company has a market cap of $230.72 billion, a PE ratio of 38.74, a PEG ratio of 2.80 and a beta of 0.77. The stock has a fifty day moving average of $570.86 and a 200-day moving average of $571.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, beating the consensus estimate of $5.13 by $0.24. The company had revenue of $10.54 billion during the quarter, compared to the consensus estimate of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same period last year, the business posted $5.15 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 21.71 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.26%. The ex-dividend date of this dividend is Friday, September 13th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analyst Ratings Changes

A number of research analysts have issued reports on TMO shares. HSBC lifted their price objective on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Jefferies Financial Group restated a “buy” rating and issued a $650.00 price objective (up previously from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. TD Cowen upped their price objective on Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Finally, Evercore ISI cut their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 2nd. Five analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $618.94.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.